Danaher Corporation (DHR)vsICICI Bank Limited (IBN)
DHR
Danaher Corporation
$171.16
-2.56%
HEALTHCARE · Cap: $124.33B
IBN
ICICI Bank Limited
$26.49
-0.93%
FINANCIAL SERVICES · Cap: $95.83B
Smart Verdict
WallStSmart Research — data-driven comparison
ICICI Bank Limited generates 8676% more annual revenue ($2.17T vs $24.78B). IBN leads profitability with a 24.9% profit margin vs 14.9%. IBN appears more attractively valued with a PEG of 0.53. IBN earns a higher WallStSmart Score of 81/100 (A-).
DHR
Buy58
out of 100
Grade: C
IBN
Exceptional Buy81
out of 100
Grade: A-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-28.4%
Fair Value
$136.83
Current Price
$171.16
$34.33 premium
Intrinsic value data unavailable for IBN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 22.9%
Generating 1.1B in free cash flow
Strong operational efficiency at 33.3%
Revenue surging 66.9% year-over-year
Large-cap with strong market position
Keeps 25 of every $100 in revenue as profit
Growing faster than its price suggests
Attractively priced relative to earnings
Areas to Watch
Premium valuation, high expectations priced in
3.7% revenue growth
ROE of 7.1% — below average capital efficiency
No major concerns identified
Comparative Analysis Report
WallStSmart ResearchBull Case : DHR
The strongest argument for DHR centers on Market Cap, Price/Book, Operating Margin. PEG of 1.11 suggests the stock is reasonably priced for its growth.
Bull Case : IBN
The strongest argument for IBN centers on Operating Margin, Revenue Growth, Market Cap. Profitability is solid with margins at 24.9% and operating margin at 33.3%. Revenue growth of 66.9% demonstrates continued momentum.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio, Revenue Growth, Return on Equity.
Bear Case : IBN
No major red flags identified for IBN, but monitor valuation.
Key Dynamics to Monitor
DHR profiles as a value stock while IBN is a growth play — different risk/reward profiles.
DHR carries more volatility with a beta of 0.84 — expect wider price swings.
IBN is growing revenue faster at 66.9% — sustainability is the question.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
IBN scores higher overall (81/100 vs 58/100), backed by strong 24.9% margins and 66.9% revenue growth. Both earn "Exceptional Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
ICICI Bank Limited
FINANCIAL SERVICES · BANKS - REGIONAL · USA
ICICI Bank Limited offers various banking products and financial services in India and internationally. The company is headquartered in Mumbai, India.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?